Exact Sciences is paying $75 million up front for U.S. rights to a colorectal cancer blood test developed by rival Freenome. If approved, Freenome’s liquid biopsy will compete with a blood test from Guardant Health.A colorectal cancer blood test candidate from Exact Sciences fell short in its pivotal study, but the company is still in […]
